Design, synthesis, and biological evaluation of 1-phenylpyrazolo[3,4-e]pyrrolo[3,4-g]indolizine-4,6(1H,5H)-diones as new glycogen synthase kinase-3β inhibitors.

Compound 5 was selected from our in-house library as a suitable starting point for the rational design of new GSK-3β inhibitors. MC/FEP calculations of 5 led to the identification of a structural class of new GSK-3β inhibitors. Compound 18 inhibited GSK-3β with an IC50 of 0.24 μM and inhibited tau phosphorylation in a cell-based assay. It proved to be a selective inhibitor of GSK-3 against a panel of 17 kinases and showed >10-fold selectivity against CDK2. Calculated physicochemical properties and Volsurf predictions suggested that compound 18 has the potential to diffuse passively across the blood-brain barrier.

[1]  S. Brewerton,et al.  An unbiased approach to identifying tau kinases that phosphorylate tau at sites associated with early Alzheimer's disease , 2012, Alzheimer's & Dementia.

[2]  Bill Wilson,et al.  Intensity of dementia through latent variable modelling (I-DeLV) in the AIBL cohort , 2012, Alzheimer's & Dementia.

[3]  E. Novellino,et al.  Identification of glycogen synthase kinase-3 inhibitors with a selective sting for glycogen synthase kinase-3α. , 2012, Journal of medicinal chemistry.

[4]  Sven Hellberg,et al.  Discovery of novel potent and highly selective glycogen synthase kinase-3β (GSK3β) inhibitors for Alzheimer's disease: design, synthesis, and characterization of pyrazines. , 2012, Journal of medicinal chemistry.

[5]  W. Thies,et al.  2008 Alzheimer’s disease facts and figures , 2008, Alzheimer's & Dementia.

[6]  Ana Martínez,et al.  GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS , 2011, Front. Mol. Neurosci..

[7]  V. Lee,et al.  Seeding of Normal Tau by Pathological Tau Conformers Drives Pathogenesis of Alzheimer-like Tangles* , 2011, The Journal of Biological Chemistry.

[8]  Yong-Jun Jiang,et al.  Structural Features Underlying Selective Inhibition of GSK3β by Dibromocantharelline: Implications for Rational Drug Design , 2011, Chemical biology & drug design.

[9]  William L. Jorgensen,et al.  Eastern extension of azoles as non-nucleoside inhibitors of HIV-1 reverse transcriptase; cyano group alternatives. , 2010, Bioorganic & medicinal chemistry letters.

[10]  P. Verhoest,et al.  Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes. , 2010, ACS chemical neuroscience.

[11]  W. L. Jorgensen.  Efficient Drug Lead Discovery and Optimization , 2009 .

[12]  Ruili Huang,et al.  Identification of aminothienopyridazine inhibitors of tau assembly by quantitative high-throughput screening. , 2009, Biochemistry.

[13]  M. Weinand,et al.  Alzheimer disease macrophages shuttle amyloid-beta from neurons to vessels, contributing to amyloid angiopathy , 2009, Acta Neuropathologica.

[14]  Keri A. Barksdale,et al.  Unregulated mitochondrial GSK3β activity results in NADH:Ubiquinone oxidoreductase deficiency , 2008, Neurotoxicity Research.

[15]  Ana Martínez,et al.  Preclinical efficacy on GSK‐3 inhibitors: Towards a future generation of powerful drugs , 2008, Medicinal research reviews.

[16]  T. Finucane,et al.  Results, Rhetoric, and Randomized Trials: The Case of Donepezil , 2008, Journal of the American Geriatrics Society.

[17]  William L. Jorgensen,et al.  Optimization of azoles as anti-human immunodeficiency virus agents guided by free-energy calculations. , 2008, Journal of the American Chemical Society.

[18]  J. Urban,et al.  2,5-Diaminopyrimidines and 3,5-disubstituted azapurines as inhibitors of glycogen synthase kinase-3 (GSK-3). , 2008, Bioorganic & medicinal chemistry letters.

[19]  William L Jorgensen,et al.  Perspective on Free-Energy Perturbation Calculations for Chemical Equilibria. , 2008, Journal of chemical theory and computation.

[20]  M. Strong,et al.  Upregulation of GSK3β expression in frontal and temporal cortex in ALS with cognitive impairment (ALSci) , 2008, Brain Research.

[21]  John Q Trojanowski,et al.  High throughput screening for small molecule inhibitors of heparin-induced tau fibril formation. , 2007, Biochemical and biophysical research communications.

[22]  B. Doble,et al.  Functional redundancy of GSK-3α and GSK-3β in wnt/β-catenin signaling shown by using an allelic series of embryonic stem cell lines , 2007 .

[23]  Michael P. Mazanetz,et al.  Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases , 2007, Nature Reviews Drug Discovery.

[24]  T. Dale,et al.  Glycogen synthase kinase 3: A key regulator of cellular fate , 2007, Cellular and Molecular Life Sciences.

[25]  M. Medina,et al.  Glycogen Synthase Kinase 3 (GSK-3) and Its Inhibitors , 2006 .

[26]  Julian Tirado-Rives,et al.  Molecular modeling of organic and biomolecular systems using BOSS and MCPRO , 2005, J. Comput. Chem..

[27]  H. Pajouhesh,et al.  Medicinal chemical properties of successful central nervous system drugs , 2005, NeuroRX.

[28]  R. Kypta.  GSK-3 inhibitors and their potential in the treatment of Alzheimer’s disease , 2005 .

[29]  Julian Tirado-Rives,et al.  Potential energy functions for atomic-level simulations of water and organic and biomolecular systems. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[30]  H. Eldar-Finkelman,et al.  Serine 332 Phosphorylation of Insulin Receptor Substrate-1 by Glycogen Synthase Kinase-3 Attenuates Insulin Signaling* , 2005, Journal of Biological Chemistry.

[31]  M. Ilyas,et al.  Wnt signalling and the mechanistic basis of tumour development , 2005, The Journal of pathology.

[32]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[33]  P. Greengard,et al.  Pharmacological inhibitors of glycogen synthase kinase 3. , 2004, Trends in pharmacological sciences.

[34]  Jesús Avila,et al.  Glycogen synthase kinase 3: a drug target for CNS therapies , 2004, Journal of neurochemistry.

[35]  R. Jope,et al.  The glamour and gloom of glycogen synthase kinase-3. , 2004, Trends in biochemical sciences.

[36]  P. Greengard,et al.  Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases. , 2004, Journal of medicinal chemistry.

[37]  P. Greengard,et al.  GSK-3-selective inhibitors derived from Tyrian purple indirubins. , 2003, Chemistry & biology.

[38]  S. Knapp,et al.  Structural characterization of the GSK-3beta active site using selective and non-selective ATP-mimetic inhibitors. , 2003, Journal of molecular biology.

[39]  G L Snyder,et al.  Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25. , 2000, European journal of biochemistry.

[40]  J W Yates,et al.  Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. , 2000, Chemistry & biology.

[41]  B Testa,et al.  Predicting blood-brain barrier permeation from three-dimensional molecular structure. , 2000, Journal of medicinal chemistry.

[42]  John X. Morris,et al.  Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. , 1998, Science.

[43]  Ronald C. Petersen,et al.  Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17 , 1998, Nature.

[44]  T. Dale,et al.  Signal transduction by the Wnt family of ligands. , 1998, The Biochemical journal.

[45]  K. Kosik,et al.  Selective Phosphorylation of Adult Tau Isoforms in Mature Hippocampal Neurons Exposed to Fibrillar Aβ , 1997, Molecular and Cellular Neuroscience.

[46]  W. L. Jorgensen,et al.  Development and Testing of the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic Liquids , 1996 .

[47]  Bradley T. Hyman,et al.  Distribution of Alzheimer‐type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease , 1992, Neurology.

[48]  Bradley T. Hyman,et al.  Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease , 1992, Neurology.

[49]  J. Woodgett,et al.  Molecular cloning and expression of glycogen synthase kinase‐3/factor A. , 1990, The EMBO journal.

[50]  R. Silvestri,et al.  Potential antitumor agents. III. Synthesis of pyrazolo[3,4‐e]pyrrolo[3,4‐g]indolizine and 1H‐pyrazolo[3,4‐e]indolizine derivatives , 1989 .

[51]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[52]  P. Cohen,et al.  Glycogen synthase kinase-3 from rabbit skeletal muscle. , 1981, Methods in enzymology.

[53]  Gabriele Cruciani,et al.  Molecular fields in drug discovery: getting old or reaching maturity? , 2010, Drug discovery today.

[54]  B. Doble,et al.  Functional redundancy of GSK-3alpha and GSK-3beta in Wnt/beta-catenin signaling shown by using an allelic series of embryonic stem cell lines. , 2007, Developmental cell.

[55]  J. Hardy,et al.  Alzheimer's disease: the amyloid cascade hypothesis: an update and reappraisal. , 2006, Journal of Alzheimer's disease : JAD.

[56]  J. Woodgett,et al.  cDNA cloning and properties of glycogen synthase kinase-3. , 1991, Methods in enzymology.

[57]  P. Cohen,et al.  Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. , 1980, European journal of biochemistry.

[58]  E. Stenhagen,et al.  Preparation of Cis- and Trans 2,5-Dimethoxy-2-(acetamidomethyl)-2,5-dihydrofuran, of Cis- and Trans 2,5-Dimethoxy-2-(acetamidomethyl)-tetrahydrofuran and of 1-Phenyl-2-(acetamidomethyl)-pyrrole. , 1952 .